Literature DB >> 19135770

Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors.

Bart A Nijmeijer1, Karoly Szuhai, Henriëtte M Goselink, Marianke L J van Schie, Marja van der Burg, Danielle de Jong, Erik W Marijt, Oliver G Ottmann, Roel Willemze, J H Frederik Falkenburg.   

Abstract

OBJECTIVE: B-lineage acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia in lymphatic blastic phase in adults have poor prognoses despite intensive chemotherapy. Novel targeted treatment modalities emerge, but their evaluation requires relevant in vitro models of lymphoblastic leukemia. Presently available cell lines do not fully represent this heterogeneous disease. Available in vitro culturing protocols do not support long-term proliferation of primary cells. We therefore aimed to develop a culture system that allows long-term proliferation of primary human B-lineage lymphoblastic leukemia.
MATERIALS AND METHODS: Primary lymphoblastic leukemia cells were cultured in a defined serum-free medium, in the absence or presence of human hematopoietic growth factors or serum.
RESULTS: In the defined serum-free medium, cells from 12 of 34 cases immediately proliferated in vitro. In the absence of hematopoietic growth factors and serum these cases proliferated for more than 1 year without signs of exhaustion. The culturing system supported different subtypes of lymphoblastic leukemia. Two chronic myeloid leukemia in lymphatic blastic phase, four bcr/abl-positive ALL, one etv6/abl-positive ALL, 2 e2a-pbx1-positive ALL, and one t(9;11)-positive ALL could be long-term expanded, as well as two ALL that displayed nontypical cytogenetics. Not all bcr/abl- or e2a-pbx1-positive ALL proliferated in vitro, demonstrating heterogeneity within these subtypes. The proliferating bcr/abl- and etv6/abl-positive cells displayed sensitivity to imatinib, demonstrating that their proliferation depended on the activity of these oncoproteins.
CONCLUSION: The serum-free culturing system may be a valuable instrument in the study of ALL cell biology, as well as in the evaluation of novel targeted therapeutics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19135770     DOI: 10.1016/j.exphem.2008.11.002

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  27 in total

1.  PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

Authors:  A A Mian; A Rafiei; I Haberbosch; A Zeifman; I Titov; V Stroylov; A Metodieva; O Stroganov; F Novikov; B Brill; G Chilov; D Hoelzer; O G Ottmann; M Ruthardt
Journal:  Leukemia       Date:  2014-11-14       Impact factor: 11.528

2.  p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.

Authors:  Afsar A Mian; Anna Metodieva; Yousef Najajreh; Oliver G Ottmann; Jamal Mahajna; Martin Ruthardt
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

3.  BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.

Authors:  Sarah E Alford; Anisha Kothari; Floris C Loeff; Joshua M Eichhorn; Nandini Sakurikar; Henriette M Goselink; Robert L Saylors; Inge Jedema; J H Frederik Falkenburg; Timothy C Chambers
Journal:  Cancer Res       Date:  2015-02-03       Impact factor: 12.701

4.  Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation.

Authors:  Magdalena Delgado; Anisha Kothari; Walter N Hittelman; Timothy C Chambers
Journal:  J Vis Exp       Date:  2017-11-10       Impact factor: 1.355

5.  Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo.

Authors:  A Alsadeq; S Strube; S Krause; M Carlet; I Jeremias; C Vokuhl; S Loges; J A Aguirre-Ghiso; A Trauzold; G Cario; M Stanulla; M Schrappe; D M Schewe
Journal:  Leukemia       Date:  2015-06-24       Impact factor: 11.528

6.  Cell Cycle-Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells.

Authors:  Anisha Kothari; Walter N Hittelman; Timothy C Chambers
Journal:  Cancer Res       Date:  2016-05-06       Impact factor: 12.701

7.  Microtubules play an essential role in the survival of primary acute lymphoblastic leukemia cells advancing through G1 phase.

Authors:  Magdalena Delgado; Timothy C Chambers
Journal:  Cell Cycle       Date:  2018-07-31       Impact factor: 4.534

8.  A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy.

Authors:  Miranda H Meeuwsen; Anne K Wouters; Lorenz Jahn; Renate S Hagedoorn; Michel G D Kester; Dennis F G Remst; Laura T Morton; Dirk M van der Steen; Christiaan Kweekel; Arnoud H de Ru; Marieke Griffioen; Peter A van Veelen; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Mol Ther       Date:  2021-08-08       Impact factor: 11.454

9.  Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K.

Authors:  Afsar Ali Mian; Isabella Haberbosch; Hazem Khamaisie; Abed Agbarya; Larissa Pietsch; Elizabeh Eshel; Dally Najib; Claudia Chiriches; Oliver Gerhard Ottmann; Oliver Hantschel; Ricardo M Biondi; Martin Ruthardt; Jamal Mahajna
Journal:  Ann Hematol       Date:  2021-06-10       Impact factor: 3.673

10.  Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.

Authors:  Afsar Ali Mian; Anna Metodieva; Susanne Badura; Mamduh Khateb; Nili Ruimi; Yousef Najajreh; Oliver Gerhard Ottmann; Jamal Mahajna; Martin Ruthardt
Journal:  BMC Cancer       Date:  2012-09-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.